LiveWorld, Inc. (LVWD: OTC Pink Limited) | LiveWorld

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
LiveWorld, Inc. (LVWD: OTC Pink Limited) | LiveWorld Reports First Quarter Financial Results

LiveWorld, Inc. (OTC Markets: LVWD), today announced the financial results for the first quarter of 2014. Total revenues were approximately $3.3 million for the first quarter as compared to the approximately $3.9 million in total revenues reported for 2013.

The Company reported a net loss for the quarter of approximately $307,000, or 9% of total revenues. This compares to net income of approximately $285,000, or 7% of total revenues, reported for the first quarter of 2013. The earnings / (loss) per share on a fully diluted basis were $(0.01) and $0.01 for the first quarters of 2014 and 2013, respectively.

The company finished the first quarter with approximately $4.3 million in cash and cash equivalents as compared to the approximately $2.5 million at the end of the first quarter in 2013. The Company reported a positive working capital balance of approximately $3.6 million as of March 31, 2014 as compared to the approximately $3.8 million as of March 31, 2013.

“Our first quarter results are consistent with our 2014 projections, in particular continuing to transition the business from our legacy revenue in web sites to the general social web and making deeper investments in product development and expansion of sales and marketing.” said David Houston, Chief Financial Officer of LiveWorld. “We are investing in our future, and developing new revenue streams will help diversify and grow our client base.”

Detailed financial information may be downloaded at www.liveworld.com (financials page) or at www.otcmarkets.com

About LiveWorld

LiveWorld is a social content marketing company. Through a combination of software and services we provide strategy, engagement, moderation, and insight to help brands develop deeper relationships with customers. We bring a human touch scaled by technology that creates value out of user content and provides big cost savings. By providing software and services, LiveWorld delivers a full range of social media solutions to improve relationship marketing, customer support, and market learning. Fortune 500 brands use our solutions to engage their clients in a way that’s social, personal, and direct, yet affordable and sustainable on a large scale. Our proprietary technology empowers people to moderate and respond to user comments at scale and to analyze data in context with human intelligence and sensitivity. LiveWorld is a trusted partner of the world’s largest brands, including the number-one companies in retail, CPG, pharmaceutical, and financial/travel services. For our clients, we develop strategy, create and publish content, engage customers, moderate content, manage crises, and glean insight from social media. LiveWorld is headquartered in California, with offices in New York City and San Jose. Learn more at www.liveworld.com and @LiveWorld

“Safe Harbor" Statement Under The Private Securities Litigation Reform Act

This press release may contain forward-looking information concerning LiveWorld's plans, objectives, future expectations, forecasts and prospects. These statements may include those regarding LiveWorld’s current or future financial performance including but not limited to lists of clients, revenue and profit, use of cash, investments, relationships and the actual or potential impact of stock option expense, and the results of its product development efforts. Actual results may differ materially from those expressed in the forward looking statements made as a result of, among other things, final accounting adjustments and results, LiveWorld’s ability to attract new clients and preserve or expand its relationship with existing clients, LiveWorld’s ability to retain and attract high quality employees, including its management staff, the ability to deliver new innovative products in a timely manner, changing accounting treatments, and other risks applicable to the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to update these forward-looking statements to reflect subsequent events or circumstances.

 
LIVEWORLD, INC.
BALANCE SHEETS
(In thousands)
   
March 31, December 31,
2014 2013
ASSETS
Current assets
Cash and cash equivalents $ 4,317 $ 4,413
Accounts receivable 365 488
Prepaid expenses   336     336  
Total current assets 5,018 5,237
 
Property and equipment, net 239 257
Other assets   17     18  
Total assets $ 5,274   $ 5,512  
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable $ 372 $ 159
Accrued employee expenses 596 576
Other accrued liabilities 59 6
Deferred revenue   386     665  
Total current liabilities   1,413     1,406  
 
 
Stockholders' equity

Common stock: $0.001 par value, 100,000,000 shares authorized 33,321,634 issued and outstanding as of March 31, 2014 and December 31, 2013,

33 33
Additional paid-in capital 141,510 141,448
Accumulated deficit   (137,682 )   (137,375 )
Total stockholders' equity   3,861     4,106  
Total liabilities and stockholders' equity $ 5,274   $ 5,512  
 
 
LIVEWORLD, INC.
STATEMENTS OF OPERATIONS
(In thousands, except per share data)
   

Three Months Ended
March 31,

2014 2013
Total revenues $ 3,311 $ 3,874
Cost of revenues   1,411     1,362
Gross Margin 1,900 2,512
Operating Expenses
Product development 900 1,021
Sales and marketing 548 498
General and administrative   748     702
Total operating expenses   2,196     2,221
Income / (loss) before tax (296 ) 291
Provision for income taxes 11 6
Net income/ (loss)   (307 )   285
 
Basic net income/ (loss) per share $ (0.01 ) $ 0.01
Shares used in computing basic income/ (loss) per share 33,321,634 33,257,634
Diluted income/ (loss) per share $ (0.01 ) $ 0.01
Shares used in computing diluted income/ (loss) per share 33,321,634 41,707,087
 
Departmental allocation of stock-based compensation:
Cost of revenues $ 11 $ 8
Product development 19 12
Sales and marketing 12 5
General and administrative   20     8
Total stock-based compensation $ 62   $ 33
 
 
LIVEWORLD, INC.
STATEMENTS OF CASH FLOWS
(In thousands)
 
Three Months Ended
March 31,
2014   2013
Cash flows from operating activities:
Net income $ (307 ) $ 285
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation 39 29
Stock-based compensation 62 33
Changes in operating assets and liabilities:
Accounts receivable 123 (1,030 )
Other assets 1 33
Accounts payable 213 140
Accrued employee expenses and other liabilities 73 154
Deferred revenue   (279 )   (502 )
Net cash provided by operating activities   (75 )   (858 )
Cash flows from investing activities:
Purchases of property and equipment   (21 )   (21 )
Net cash used in investing activities   (21 )   (21 )
Change in cash and cash equivalents (96 ) (879 )
Cash and cash equivalents, beginning of year   4,413     3,382  
Cash and cash equivalents, end of year $ 4,317   $ 2,503  
 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 262

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 135

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 718

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 314

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 187

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 255

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 63

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 129

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 287

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 62

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading

Top 5 Most Recently Viewed Articles

Elis Announces Share Buyback Operations Details and Impact

Updated Category News Views 257

Elis Announces Share Buyback Operations Recent Trading Disclosure by Elis In alignment with European regulations governing share buybacks, Elis has disclosed transactions for the purchase of its own shares. These operations occurred from September 15 to September 19, 2025, as part of an authorized buyback program approved by the General Shareholders' Meeting earlier in...

Continue Reading
One Stop Systems Set To Showcase Innovations at ROTH Event

Updated Category News Views 122

One Stop Systems Announces Participation in Major Conference One Stop Systems, Inc. (OSS), renowned for its cutting-edge solutions in rugged Enterprise Class computing, is gearing up to engage with investors at a prominent industry event. This year, OSS will be present at the 37th Annual ROTH Conference, scheduled for mid-March. The event will serve as a platform for the...

Continue Reading
Solid Biosciences to Engage at BioPharma Symposium Soon

Updated Category News Views 80

Solid Biosciences to Participate at BioPharma Symposium Solid Biosciences Inc. (NASDAQ: SLDB), a pioneering life sciences company, is excited to announce a significant upcoming event where they will showcase their advancements in the field of precision genetic medicine. The company's Chief Medical Officer, Dr. Gabriel Brooks, is scheduled to participate in a Genetic...

Continue Reading
JD Vance Confronted by Protesters While Out with Daughter

Updated Category News Views 378

Intense Encounter for Vice President JD Vance Recently, Vice President JD Vance found himself in a challenging situation when he was confronted by a group of pro-Ukraine protesters while spending time with his daughter. This encounter, which took place in Ohio, captured not only the essence of political tensions but also brought forth the complexities of personal moments...

Continue Reading
Exciting Addition to MyCardiologist as Dr. Koshy Joins Team

Updated Category News Views 325

New Addition to MyCardiologist Enhances Cardiovascular Care MyCardiologist, a leading name in advanced cardiovascular care, proudly announces the joining of Dr. Linda Koshy to their reputable medical team. Dr. Koshy is a skilled general and interventional cardiologist known for her exceptional ability to manage intricate coronary artery disease as well as endovascular...

Continue Reading